08/12/2017 00:08:33

Denali Therapeutics Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of 13,888,888 shares of its common stock at a price to the public of $18.00 per share. In addition, the underwriters have a 30-day option to purchase up to 2,083,333 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the NASDAQ Global Select Market on December 8, 2017 under the symbol “DNLI.” The offering is expected to close on December 12, 2017, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering, and Evercore Group L.L.C. is acting as lead manager for the offering.

The offering is made only by means of a prospectus. When available, a copy of the final prospectus relating to this offering may be obtained from:

Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: prospectusgroup-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: prospectus-eq_fi@jpmchase.com.

A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Denali

Denali is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali is based in South San Francisco.

CONTACT:

Lizzie Hyland

(646) 495-2706

lhyland@gpg.com

or

Morgan Warners

(202) 295-0124

mwarners@gpg.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Oct
DANSKE
Stop dog for helvede dine sindsyge indlæg. Det er brugere som dig der fuldkommen smadrer det her for..
27
11 Oct
OMXC25
... og det betyder som regel, at det er sidste ben i nedturen, før en pause, eller en positiv modrea..
24
12 Oct
DANSKE
Ole Andersen havde ansat 5 kanibaler til at ryde op efter hvidvasskandalen. I har nu fast arbejde, t..
21
13 Oct
PNDORA
Carnegie's seneste analyse gav lidt medvind til pandora, men det var slet ikke meningen, idet alle j..
20
10 Oct
DANSKE
TYVERI FOR 100 MILLIONER - DANSKE BANKS ANSVAR?Igår kom en historie om en kvinde, der systematisk ig..
18
14 Oct
DANSKE
En korruptionsbekæmper skudt i Moskva, er nu også blevet Danske Banks skyld, hvor ussel kan denne p..
17
12 Oct
DANSKE
Der er noget ejendommeligt ved danmarkshistoriens formentlig største pengeinstitutskandale: Formentl..
15
13 Oct
CHEMM
@Tommy, Du stiller et meget relevant spørgsmål, men først vil jeg korrigere lidt på dit P/E. Som inv..
14
12 Oct
VELO
Blot til orientering. Kursudvikling i Veloxis vs. øvrige danske biotek/medico seneste måned: Velo..
14
15 Oct
OMXC25
Jeg har tænkt over den seneste uges udvikling. Min globale-US-dollars-allokerings-model (GUSDAM) vis..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
2
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
3
JCDecaux: Update on JCDecaux's proposed acquisition of APN Outdoor in Australia
4
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
5
ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 October 2018 01:09:18
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB5 - 2018-10-16 02:09:18 - 2018-10-16 01:09:18 - 1000 - Website: OKAY